Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug ...

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee ...

Capricor on Tuesday disclosed that the FDA has indicated that no AdCom is necessary for deramiocel’s Biologics License ...

Deramiocel is an Investigational New Drug (IND) and is not yet approved for any indications. Neither BMD nor any of Capricor’s exosome-based candidates have been approved for clinical use.

Capricor Therapeutics leads with Deramiocel for DMD and StealthX tech, backed by trials, NS Pharma deal, and cash. See why CAPR stock is a buy.

Deramiocel (also known as CAP-1002) is a cell therapy being developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy.

Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients--Improvements See ...

Deramiocel (CAP-1002) is a drug that's focused on treating DMD-associated cardiomyopathy, the weakening of the heart muscle. It's an allogeneic cell therapy that uses cardiosphere-derived cells ...

“Deramiocel has shown in multiple clinical trials attenuation of DMD cardiomyopathy, which is currently one of the leading causes of death in those with DMD,” said Craig McDonald, MD, national ...

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy. Capricor Therapeutics .